China's Connect Biopharma Announces IPO At $17/ADS

By RTTNews Staff Writer   ✉   | Published:

Connect Biopharma Holdings Ltd on Thursday said it has priced its Initial Public Offering of 11.25 million American Depositary Shares at $17 per ADS.

The Chinese clinical-stage biopharmaceutical company said that the ADSs will begin trading on the Nasdaq from Friday, under the symbol "CNTB". The IPO is expected to close on March 23.

The total proceeds from the IPO are expected to be around $191.3 million.

The company has given underwriters an option to purchase up to an additional 1.69 million ADSs within 30 days from the final prospectus date at the IPO price.

The gross proceeds from the offering will be $220 million if the underwriters buy additional ADSs in full.

Jefferies LLC, SVB Leerink LLC, Piper Sandler & Co. and China International Capital Corp. Hong Kong Securities Limited are the joint book-running managers for this offering.

For comments and feedback contact: editorial@rttnews.com

Business News

Previous Story
Next Story
Editors Pick
Genentech Recalls Prescription Drug Evrysdi
Genentech, a member of Swiss drug major Roche Group, is recalling prescription drug Evrysdi or risdiplam as it failed to meet child resistant packaging requirements, according to the U.S. Consumer Product Safety Commission. The recall involves about 14,000 units of Evrysdi, a prescription medicine used to treat spinal muscular atrophy or SMA in adults and children 2 months of age and older.
Walmart To Help People Access Their Covid-19 Vaccine Records
Walmart Inc. is helping people to digitally access their health records, starting with COVID-19 vaccine records, in a convenient, safe, secure and frictionless way. To implement this, the retail giant will use the open, interoperable SMART Health Cards standard that is being developed under the Vaccination Credential Initiative, co-chaired by The Commons Project Foundation.
HeidelbergCement Q4 Profit Up, Lifts Dividend; Sees Growth In FY21 Results
HeidelbergCement reported Thursday higher profit in its fourth quarter, despite a decline in revenues. Cement and Aggregates volume increased, while ready-mixed concrete volume were down. Looking ahead, the German building materials company reported good start to the year and confirmed optimistic outlook for 2021. Demand is expected to develop positively in many markets.